Phunchai CharatcharoenwitthayaVirasak WongpaitoonPiyawat KomolmitWattana SukeepaisarnjaroenPisit TangkijvanichTeerha PiratvisuthTheeranun SanpajitChinnavat SutthivanaChalermrat BunchorntavakulAbhasnee SobhonslidsukSoonthorn ChonprasertsukChotipong SiripipattanamongkolSupatsri SethasineTawesak TanwandeeChulalongkorn UniversityBhumibol Adulyadej HospitalBumrungrad International HospitalVajira HospitalKhon Kaen UniversityFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityThammasat UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversityPhramongkutklao College of MedicinePrince of Songkla UniversityRajavithi HospitalChiangrai Prachanukroh Hospital2020-03-262020-03-262020-03-05BMC Gastroenterology. Vol.20, No.1 (2020)1471230X2-s2.0-85081200562https://repository.li.mahidol.ac.th/handle/20.500.14594/53727© 2020 The Author(s). Background: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6. Methods: We analyzed data from 1021 patients with HCV infection (506 with genotype 1; 16 with genotype 2; 314 with genotype 3; 13 with genotype 4; 166 with genotype 6) who received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12). Results: Overall, SVR12 rate was 98.0% (95% confidence interval [CI], 96.7-98.8%) with daclatasvir plus sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir. SVR12 was achieved by 99.2% (95% CI, 97.9-99.7%) of subjects with genotype 1 infection, 100% (95% CI, 78.5-100%) of those with genotype 2 infection, 96.7% (95% CI, 94.0-98.2%) of those with genotype 3 infection, 90.9% (95% CI, 62.3-98.4%) of those with genotype 4 infection, and 96.7% (95% CI 92.5-98.6%) of those with genotype 6 infection. Patients with advanced liver disease were at risk of treatment failure. Only four patients discontinued treatment before week 4 due to non-hepatic adverse events. Conclusions: In this large cohort of patients with various HCV genotypes managed in the real-world practice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good safety profile, comparable to those observed in clinical trials.Mahidol UniversityMedicineArticleSCOPUS10.1186/s12876-020-01196-0